Production and Functional Assays of Recombinant Secreted Amyloid Precursor Protein (APP) (sAPPα)

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• The beta-amyloid precursor protein (APP) is genetically and biochemically linked to Alzheimer's disease (AD).
• Amyloid plaques, composed of amyloid-beta peptide (Aβ), are a hallmark of AD, suggesting abnormal APP processing.
• The Amyloid Hypothesis posits that Aβ actions cause AD's clinical and pathological features.

Purpose of the Study:

• To explore alternative theories linking APP to Alzheimer's disease beyond the established Amyloid Hypothesis.
• To investigate the non-amyloidogenic processing pathway of APP via alpha-secretase.
• To understand the functional implications of soluble APP-alpha (sAPPα) and its role in AD pathogenesis.

Main Methods:

• Review of existing literature on APP processing and Alzheimer's disease.
• Analysis of APP's biochemical pathways, including alpha-secretase and beta-secretase cleavage.
• Examination of genetic mutations (e.g., Swedish mutation) and chromosomal abnormalities (e.g., trisomy 21) affecting APP levels.

Main Results:

• APP can be processed via alpha-secretase, cleaving within the Aβ sequence and precluding Aβ generation.
• This non-amyloidogenic pathway releases soluble APP-alpha (sAPPα), distinct from the sAPPβ generated through beta-secretase cleavage.
• Increased APP expression (due to injury or trisomy 21) can elevate total sAPP levels, potentially impacting sAPPα-dependent functions.

Conclusions:

• The Amyloid Hypothesis, while influential, does not encompass all potential links between APP and Alzheimer's disease.
• Elucidating the biological activities of sAPPα is crucial for understanding normal APP functions and their disruption in AD.
• Further research into non-amyloidogenic APP processing is necessary to develop comprehensive AD therapeutic strategies.